Us Bancorp \De\ Cytom X Therapeutics, Inc. Transaction History
Us Bancorp \De\
- $77.3 Billion
- Q3 2024
A detailed history of Us Bancorp \De\ transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 33,792 shares of CTMX stock, worth $29,736. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,792Holding current value
$29,736% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding CTMX
# of Institutions
71Shares Held
50.7MCall Options Held
112KPut Options Held
8.3K-
Tang Capital Management LLC San Diego, CA7.81MShares$6.87 Million0.79% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$4.6 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.16MShares$4.54 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X04.81MShares$4.23 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.1MShares$2.73 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $58M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...